CTC Survey Results Released

Inbox

x

Andrew Kerry	3:08 AM (3 hours ago)
to me

  Dear MUTOMBO,

We recently ran a survey on Circulating Tumour Cells which questioned stakeholders across drug development, academia, cancer hospitals and the technology sector on the  challenges that they are facing in utilising CTCs in their research.  I think you’ll find the results interesting: 74.3% of respondents in the survey highlighted CTCs as either a "very high" or  "high priority" for their organisation When questioned what was the biggest challenges faced in this field the top  challenge was identified as “Current technology is neither sensitive or specific  enough” (33%) with the second biggest challenge being that “There is no agreed  golden standard for technology” (25.5%) A resounding 48.8% thought that to validate CTCs in the clinic there needs to be  “more clinical trials validating CTCs as a diagnostic/prognostic prospective” These are just some of the revealing answers the survey uncovered. You can download the full survey results from the World CTC Berlin Library. In addition to these exciting results I’d also like to take the opportunity to announce the latest speaker for World CTC Berlin: Sarah Thayer, Associate Professor, Surgery, W. Gerald Austen Scholar in Academic Surgery & Director, Pancreatic Biology Laboratory, Mass Gen Hospital Presentation Title: The Capture, Growth and Genetic Analysis of CTC in PDAC: What  Can it Tell Us About this Disease? Detection of CTC in patients with resectable PDAC using a Screencells Device Methods used to achieve in vitro growth and confirmation of tumorigenicity How selective deep sequencing was used to demonstrate the feasibility of  identifying mutations present in the primary tumour and their corresponding CTC Download the meeting brochure to see the full array of CTC experts on the programme. Kind regards Andrew Andrew Kerry Hanson Wade www.worldctc-berlin.com